FDA approves Zepzelca (lurbinectedin) for treatment of advanced SCLC that has progressed after platinum chemotherapy
On June 15, 2020, the Food and Drug Administration (FDA) approved Zepzelca (lurbinectedin) for treatment of advanced small cell lung cancer (SCLC) whose cancer has progressed after platinum chemotherapy.
On June 15, 2020, the Food and Drug Administration (FDA) approved Zepzelca (lurbinectedin) for treatment of advanced small cell lung cancer (SCLC) whose cancer has progressed after platinum chemotherapy.
